Abstract 1482P
Background
More than 80% patients of Carcinoma Gall bladder (Ca GB) present with unresectable or disseminated disease. In these patients jaundice can be very distressing leading to poor quality of life (QOL) PTBD has been advocated to palliate this but, its impact on QOL has not been adequately studied.
Methods
Prospective observational study over two years included patients of proven unresectable/disseminated Ca GB presenting with jaundice. Pre-procedure parameters were recorded and PTBD done. Quality of Life (QOL) was assessed by EORTC QLQ-C30 and BIL-21 scores prior to the treatment and after 1- month. Post procedure complications were reported. Follow up was done at 1,3 and 6 months.
Results
Study included 43 patients of unresectable/disseminated Ca GB. Median age was 52 years with 74% females. 26 patients underwent unilateral (U/L) and 17 bilateral (B/L) PTBD. 4 patients needed B/L PTBD for inadequate bilirubin fall at 4 weeks. Mean serum bilirubin was 18.3 ± 7.3 mg/dl, albumin was 2.9 ± 0.5 mg/dl and INR was 1.7 ± 1.2. Commonest indication for PTBD was pruritus (65%) and only 12% patients had cholangitis. Bilirubin level at 1 week and 1 month was 15mg/dl and 7.1 mg/dl respectively(p=0.0002). Unfortunately, EORTC QLQ-C30 QOL scores showed decline in all aspects at 1 months and 3 months. Even in BIL-21 scores although there was improvement in Jaundice scale those with anxiety, pain and side effects had decline. Most patients had morbidity related to either slippage of PTBD or peri-tubal leakage. Also, inevitability of disease progression due to lack of treatment caused significant anxiety. 4 patients expired within 30 days due to cholangitis. Survival at 1-, 3- and 6- months was 60%, 23% and 7% respectively with median survival of 38 days.
Conclusions
Although jaundice is a fairly debilitating symptom in patients with unresectable Ca GB, palliation in form of PTBD may not always lead to improvement of QOL. Psychological counselling and proper guidance in terms of care of drains as well proper pain management is imperative to provide these terminally ill patients with best supportive care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. Galodha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10